Axsome bounces back as FDA clears depression drug
pharmaphorum
AUGUST 21, 2022
The biotech hasn’t revealed much information about the reasons for the delay in getting approval, but said in an SEC filing in June this year that it had agreed to “post-marketing commitments” proposed by the FDA, without going into details.
90 
Let's personalize your content